Drugs

, Volume 71, Issue 15, pp 2009–2030

Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions

  • H. Benjamin Starnes
  • Ankit A. Patel
  • George A. Stouffer
Review Article

Abstract

Discovery of the central role of platelets in the pathogenesis of acute coronary syndromes (ACS) and ischaemic complications of percutaneous coronary interventions (PCI) has led to the widespread use of oral and parenteral platelet inhibitors to treat these conditions. Glycoprotein (GP) IIb/IIIa (also known as αIIbβ3) receptors on the surface of platelets play an essential role in platelet aggregation and serve as a key mediator in the formation of arterial thrombus. When activated, GP IIb/IIIa receptors bind to fibrinogen, which serves as the ‘final common pathway’ in platelet aggregation. Of the numerous agents developed for modulating platelet activity, intravenous platelet GP IIb/IIIa receptor antagonists are the most potent.

There are four agents in clinical use, including abciximab, eptifibatide, tirofiban and lamifiban, although lamifiban is not approved for use in the US. While all agents block fibrinogen binding to GP IIb/IIIa, they do so by different mechanisms. Abciximab is a humanized form of a murine monoclonal antibody directed against GP IIb/IIIa, eptifibatide is a synthetic, cyclic heptapeptide that contains a lysine-glycine-aspartic acid (KGD) sequence that mimics the arginine-glycine-aspartic acid (RGD) sequence found on GP IIb/IIIa, tirofiban is a non-peptide antagonist derived by optimization of the tyrosine analogue that structurally mimicks the RGD-containing loop of the disintegrin echistatin, and lamifiban is a synthetic, non-cyclic, non-peptide, low-molecular-weight compound. In clinical trials, use of these agents reduces ischaemic adverse cardiovascular events in patients with ACS undergoing PCI, but at a cost of increased bleeding.

References

  1. 1.
    Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010 Oct; 31(20): 2501–55PubMedGoogle Scholar
  2. 2.
    Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007 Aug 14; 50(7): e1–157PubMedGoogle Scholar
  3. 3.
    King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008 Jan 15; 51(2): 172–209PubMedGoogle Scholar
  4. 4.
    Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008 Dec; 29(23): 2909–45PubMedGoogle Scholar
  5. 5.
    Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) — a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009 Dec 1; 54(23): 2205–41PubMedGoogle Scholar
  6. 6.
    Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983 Aug 18; 309(7): 396–403PubMedGoogle Scholar
  7. 7.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985 Nov 28; 313(22): 1369–75PubMedGoogle Scholar
  8. 8.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988 Oct 27; 319(17): 1105–11PubMedGoogle Scholar
  9. 9.
    The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990 Oct 6; 336(8719): 827–30Google Scholar
  10. 10.
    Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988 Jun 30; 318(26): 1714–9PubMedGoogle Scholar
  11. 11.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 1988 Aug 13; 2(8607): 349–60Google Scholar
  12. 12.
    Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010 Jul 27; 122(4): 394–403PubMedGoogle Scholar
  13. 13.
    Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009 Aug; 30(16): 1964–77PubMedGoogle Scholar
  14. 14.
    Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001 Jan 16; 103(2): 201–6PubMedGoogle Scholar
  15. 15.
    Tran H, Anand SS. Oral antiplatelet therapy in cerebro-vascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004 Oct 20; 292(15): 1867–74PubMedGoogle Scholar
  16. 16.
    Mannucci PM. Treatment of von Willebrand’s Disease. N Engl J Med 2004 Aug 12; 351(7): 683–94PubMedGoogle Scholar
  17. 17.
    Italiano Jr JE, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost 2003 Jun; 1(6): 1174–82Google Scholar
  18. 18.
    Fozzard HA. The Heart and cardiovascular system: scientific foundations. 2nd ed. New York: Raven Press, 1991Google Scholar
  19. 19.
    Plow EF, McEver RP, Coller BS, et al. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985 Sep; 66(3): 724–7PubMedGoogle Scholar
  20. 20.
    Haverstick DM, Cowan JF, Yamada KM, et al. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985 Oct; 66(4): 946–52PubMedGoogle Scholar
  21. 21.
    Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987 Oct 23; 238(4826): 491–7PubMedGoogle Scholar
  22. 22.
    Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986 Feb 28; 44(4): 517–8PubMedGoogle Scholar
  23. 23.
    D’Souza SE, Ginsberg MH, Plow EF. Arginyl-glycylaspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991 Jul; 16(7): 246–50PubMedGoogle Scholar
  24. 24.
    Phillips DR, Charo IF, Parise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988 Apr; 71(4): 831–43PubMedGoogle Scholar
  25. 25.
    Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996 Aug 1; 88(3): 907–14PubMedGoogle Scholar
  26. 26.
    Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem 1982 Sep 10; 257(17): 10458–66PubMedGoogle Scholar
  27. 27.
    Woods Jr VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986 Nov 15; 261(32): 15242–51PubMedGoogle Scholar
  28. 28.
    Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977 Sep; 60(3): 535–45PubMedGoogle Scholar
  29. 29.
    Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999 Jan; 103(2): 229–38PubMedGoogle Scholar
  30. 30.
    Kouns WC, Fox CF, Lamoreaux WJ, et al. The effect of glycoprotein IIb-IIIa receptor occupancy on the cytoskeleton of resting and activated platelets. J Biol Chem 1991 Jul 25; 266(21): 13891–900PubMedGoogle Scholar
  31. 31.
    Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002 Sep 1; 22(9): 1381–9PubMedGoogle Scholar
  32. 32.
    Vidwan P, Pathak A, Sheth S, et al. Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol Dec; 30 (12): 2587-96Google Scholar
  33. 33.
    Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983 Jul; 72(1): 325–38PubMedGoogle Scholar
  34. 34.
    Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985 Jul; 76(1): 101–8PubMedGoogle Scholar
  35. 35.
    Horton MA. Adhesion receptors as therapeutic targets. Boca Raton (FL): CRC Press, 1996Google Scholar
  36. 36.
    Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 1995 Dec; 26(7): 1665–71PubMedGoogle Scholar
  37. 37.
    Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998 Sep 15; 98(11): 1085–91PubMedGoogle Scholar
  38. 38.
    Artoni A, Li J, Mitchell B, et al. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A 2004 Sep 7; 101(36): 13114–20PubMedGoogle Scholar
  39. 39.
    Lele M, Sajid M, Wajih N, et al. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001 Jul 31; 104(5): 582–7PubMedGoogle Scholar
  40. 40.
    Sajid M, Zhao R, Pathak A, et al. Alphavbeta3-integrin antagonists inhibit thrombin-induced proliferation and focal adhesion formation in smooth muscle cells. Am J Physiol Cell Physiol 2003 Nov; 285(5): C1330–8PubMedGoogle Scholar
  41. 41.
    Sajid M, Stouffer GA. The role of alpha(v)beta3 integrins in vascular healing. Thromb Haemost 2002 Feb; 87(2): 187–93PubMedGoogle Scholar
  42. 42.
    Nurden AT, Poujol C, Durrieu-Jais C, et al. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999 Dec; 19(12): 2835–40PubMedGoogle Scholar
  43. 43.
    The EPIC Investigatiors. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 Apr 7; 330(14): 956–61Google Scholar
  44. 44.
    The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 Jun 12; 336(24): 1689–96Google Scholar
  45. 45.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998 Jul 11; 352(9122): 87–92Google Scholar
  46. 46.
    Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994 Oct; 90(4): 1757–64PubMedGoogle Scholar
  47. 47.
    Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999 Aug 15; 84(4): 391–5PubMedGoogle Scholar
  48. 48.
    Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001 May 29; 103(21): 2572–8PubMedGoogle Scholar
  49. 49.
    Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial (Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide). Circulation 2002 Sep 17; 106(12): 1470–6PubMedGoogle Scholar
  50. 50.
    Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988 Mar; 77(3): 670–7PubMedGoogle Scholar
  51. 51.
    Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GP IIb/IIIa receptors. Circulation 1989 Dec; 80(6): 1766–74PubMedGoogle Scholar
  52. 52.
    Bates ER, McGillem MJ, Mickelson JK, et al. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991 Dec; 84(6): 2463–9PubMedGoogle Scholar
  53. 53.
    Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993 Jan 15; 268(2): 1066–73PubMedGoogle Scholar
  54. 54.
    Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995 Dec 15; 76(17): 1222–7PubMedGoogle Scholar
  55. 55.
    Integrilin [package insert; revised 2011 Mar]. Whitehouse Station (NJ): Merck & Co, Inc. 2011 MarGoogle Scholar
  56. 56.
    Marciniak Jr SJ, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GP IIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001 Mar; 85(3): 539–43PubMedGoogle Scholar
  57. 57.
    Kereiakes DJ, Lorenz T, Young JJ, et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 2001 Oct; 12(2): 123–7PubMedGoogle Scholar
  58. 58.
    The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet 1997 May 17; 349(9063): 1422–8Google Scholar
  59. 59.
    Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997 Sep 2; 96(5): 1488–94PubMedGoogle Scholar
  60. 60.
    Tcheng JE, Talley JD, O’Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001 Nov 15; 88(10): 1097–102PubMedGoogle Scholar
  61. 61.
    The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000 Dec 16; 356(9247): 2037–44Google Scholar
  62. 62.
    Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996 Mar 1; 27(3): 536–42PubMedGoogle Scholar
  63. 63.
    The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997 Sep 2; 96(5): 1445–53Google Scholar
  64. 64.
    Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 Jun 21; 344(25): 1888–94PubMedGoogle Scholar
  65. 65.
    Moliterno DJ, TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the Tirofiban Evaluation of Novel dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin studY (TENACITY) trial. Catheter Cardiovasc Interv 2011 Jun 1; 77(7): 1001–9PubMedGoogle Scholar
  66. 66.
    Kouns WC, Kirchhofer D, Hadvary P, et al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992 Nov 15; 80(10): 2539–47PubMedGoogle Scholar
  67. 67.
    Dooley M, Goa KL. Lamifiban. Drugs 1999 Feb; 57(2): 215–21; discussion 22-3PubMedGoogle Scholar
  68. 68.
    Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996 Sep 1; 94(5): 899–905PubMedGoogle Scholar
  69. 69.
    International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators (Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network). Circulation 1998 Jun 23; 97(24): 2386–95PubMedGoogle Scholar
  70. 70.
    The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998 Dec; 32(7): 2003–10Google Scholar
  71. 71.
    The Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002 Jan 22; 105(3): 316–21Google Scholar
  72. 72.
    Dong L, Zhang F, Shu X. Upstream vs deferred administration of small-molecule glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: insights from randomized clinical trials. Circ J 2010 Aug; 74(8): 1617–24PubMedGoogle Scholar
  73. 73.
    Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999 Dec 11; 354(9195): 2019–24Google Scholar
  74. 74.
    The PURSUIT Trial Investigators (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998 Aug 13; 339(7): 436–43Google Scholar
  75. 75.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338(21): 1498–505Google Scholar
  76. 76.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338(21): 1488–97Google Scholar
  77. 77.
    De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005 Apr 13; 293(14): 1759–65PubMedGoogle Scholar
  78. 78.
    Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001 Jun 21; 344(25): 1895–903PubMedGoogle Scholar
  79. 79.
    Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002 Mar 28; 346(13): 957–66PubMedGoogle Scholar
  80. 80.
    Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003 Dec 3; 42(11): 1879–85PubMedGoogle Scholar
  81. 81.
    Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009 Apr 14; 119(14): 1933–40PubMedGoogle Scholar
  82. 82.
    Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J Am Coll Cardiol 2010 Aug 3; 56(6): 463–9PubMedGoogle Scholar
  83. 83.
    Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001 Jun 16; 357(9272): 1915–24PubMedGoogle Scholar
  84. 84.
    The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997 May 17; 349(9063): 1429–35Google Scholar
  85. 85.
    Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002 Jan 19; 359(9302): 189–98PubMedGoogle Scholar
  86. 86.
    Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy. Eur Heart J 2002 Sep; 23(18): 1441–8PubMedGoogle Scholar
  87. 87.
    Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007 Feb 14; 297(6): 591–602PubMedGoogle Scholar
  88. 88.
    Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009 May 21; 360(21): 2176–90PubMedGoogle Scholar
  89. 89.
    Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006 Apr 5; 295(13): 1531–8PubMedGoogle Scholar
  90. 90.
    Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 Nov 23; 355(21): 2203–16PubMedGoogle Scholar
  91. 91.
    Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998 Dec 15; 98(24): 2695–701PubMedGoogle Scholar
  92. 92.
    Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008 Apr 16; 299(15): 1788–99PubMedGoogle Scholar
  93. 93.
    De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009 May 5; 53(18): 1668–73PubMedGoogle Scholar
  94. 94.
    Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008 May 22; 358(21): 2218–30PubMedGoogle Scholar
  95. 95.
    Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 May 22; 358(21): 2205–17PubMedGoogle Scholar
  96. 96.
    Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006 Feb 18; 367(9510): 579–88PubMedGoogle Scholar
  97. 97.
    Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004 Jan 15; 350(3): 232–8PubMedGoogle Scholar
  98. 98.
    Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004 Dec 14; 110(24): 3627–35PubMedGoogle Scholar
  99. 99.
    Winchester DE, Wen X, Brearley WD, et al. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol 2011 Mar 8; 57(10): 1190–9PubMedGoogle Scholar
  100. 100.
    Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002 Dec 10; 106(24): 3063–7PubMedGoogle Scholar
  101. 101.
    Marmur JD, Mitre CA, Barnathan E, et al. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am Heart J 2006 Nov; 152(5): 876–81PubMedGoogle Scholar
  102. 102.
    Bertrand OF, De Larochelliere R, Rodes-Cabau J, et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006 Dec 12; 114(24): 2636–43PubMedGoogle Scholar
  103. 103.
    Fung AY, Saw J, Starovoytov A, et al. Abbreviated infusion of eptifibatide after successful coronary intervention. The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009 Mar 10; 53(10): 837–45Google Scholar
  104. 104.
    Gu YL, Kampinga MA, Wieringa WG, et al. Intra-coronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010 Dec 21; 122(25): 2709–17PubMedGoogle Scholar
  105. 105.
    Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) trial. Circulation Feb 16; 121 (6): 784-91Google Scholar
  106. 106.
    Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003 Oct; 146(4): 628–34PubMedGoogle Scholar
  107. 107.
    Dasgupta H, Blankenship JC, Wood GC, et al. Thrombo-cytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000 Aug; 140(2): 206–11PubMedGoogle Scholar
  108. 108.
    Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004 May 11; 109(18): 2203–6PubMedGoogle Scholar
  109. 109.
    Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000 Jul; 140(1): 74–80PubMedGoogle Scholar
  110. 110.
    Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005 Feb; 127 (2 Suppl.): 53–9SGoogle Scholar
  111. 111.
    Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GP IIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GP IIb/IIIa inhibitors. J Thromb Haemost 2006 Mar; 4(3): 678–9PubMedGoogle Scholar
  112. 112.
    Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood 2002 Sep 15; 100(6): 2071–6PubMedGoogle Scholar
  113. 113.
    Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997 Aug 18; 80(4A): 11–20BGoogle Scholar
  114. 114.
    Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet 2002; 41(3): 187–95PubMedGoogle Scholar
  115. 115.
    Greinacher A, Fuerll B, Zinke H, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009 Aug 6; 114(6): 1250–3PubMedGoogle Scholar
  116. 116.
    Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006 Jan 3; 47(1): 216–35PubMedGoogle Scholar
  117. 117.
    Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28(13): 1598–660PubMedGoogle Scholar
  118. 118.
    Mehran R, Pocock S J, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010 Jun 8; 55(23): 2556–66PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • H. Benjamin Starnes
    • 1
  • Ankit A. Patel
    • 1
  • George A. Stouffer
    • 1
  1. 1.Division of CardiologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations